Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL-rearranged complex karyotype acute myeloid leukemia

Taro Edahiro; Hiroshi Ureshino; Ren Chishaki; Keita Fujino; Tatsuji Mino; Tetsumi Yoshida; Noriyasu Fukushima; Tatsuo Ichinohe

doi:10.1002/jha2.630

Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL-rearranged complex karyotype acute myeloid leukemia

EJHaem. 2022 Dec 26;4(1):273-275. doi: 10.1002/jha2.630. eCollection 2023 Feb.

Authors

Taro Edahiro¹, Hiroshi Ureshino^{1

2}, Ren Chishaki¹, Keita Fujino¹, Tatsuji Mino¹, Tetsumi Yoshida¹, Noriyasu Fukushima³, Tatsuo Ichinohe^{1

2}

Affiliations

¹ Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan.
² Next Generation Development of Genome and Cellular Therapy Program Research Institute for Radiation Biology and Medicine (RIRBM) Hiroshima University Hiroshima Japan.
³ Department of Internal Medicine Karatsu Red Cross Hospital Karatsu Japan.

Abstract

Translocation t(6;11) occurs in approximately 5% of patients with acute myeloid leukemia (AML) corresponding to 11q23/mixed lineage leukemia (MLL) rearrangement. The AF6 gene on chromosome 6q27 is the fusion partner of the MLL gene on 11q23 in t(6;11), which results in a poor prognosis. The case of a patient with 11q23/MLL-rearranged AML who successfully underwent a third allogeneic stem cell transplantation after treatment with azacitidine (AZA) and venetoclax (VEN) is presented in this article. This report suggests that a combination of AZA and VEN is an effective therapeutic approach for relapsed and refractory MLL-rearranged AML.

Keywords: 11q23/MLL‐rearranged acute myeloid leukemia; BCL‐2; azacitidine; venetoclax.

Publication types

Case Reports